Search
Displaying 431–440 of 894 results for “vision connection”
-
Dr Daniel C. Chung appointed as Chief Medical Officer of SparingVision
In the PressFormer Spark Therapeutics head of ophthalmic medical affairs, responsible for the development and approval of Luxturna™, to lead development of SparingVision’s proprietary asset, SPVN06, and further pipeline development
-
Stargazer Pharmaceuticals Initiates a Phase 2a Clinical Trial for its Stargardt Disease Drug
In the PressThe Foundation Fighting Blindness Retinal Degeneration Fund is an investor in the company
-
4D Molecular Therapeutics Launches Phase 1 Clinical Trial for Choroideremia Gene Therapy
Research NewsGene therapy delivered by intravitreal injection
-
Research News
With a founding investment from Hatteras Venture Partners, Atsena has raised a total of $8.15 million for its launch.
-
Beacon Stories
Tracy was the fourth generation of his family to receive the diagnosis of retinitis pigmentosa, but he never let that stop him from dreaming big. Tracy has worked at NASA’s Johnson Space Center for over 36 years, making significant contributions over the many years.
-
Positive Interim Clinical Trial Results for Adverum’s Wet AMD Gene Therapy
Research NewsThe gene therapy is designed to reduce the treatment burden for patients
-
Beacon Stories
Carolyn is a business professional and beauty industry leader in Raleigh, North Carolina. In spite of her diagnosis with retinitis pigmentosa, Carolyn pursues exactly what she wants and knows what she is purposed to do in her life.
-
A diagnosis of an inherited retinal disease (IRD) can be challenging for both patients and their doctors. But the Foundation can help eye care professionals provide resources and information to enable patients to better understand and manage their conditions, and potentially qualify for clinical trials of emerging therapies.
-
First Human Study in US for Induced Pluripotent Stem Cells to be Launched for Advanced Dry AMD
Research NewsCurrently there are no treatments for Advanced Dry AMD, also known as GA, which can lead to significant central vision loss
-
First Patient Receives ProQR’s AON Therapy in Clinical Trial for RP Caused by RHO-P23H Mutation
Research NewsThe trial becomes ProQR’s third human study for inherited retinal disease therapies
